TACE as a bridge therapy maintaining transplant candidacy for HCC patients awaiting liver transplantation represents a critical clinical application, with the Transarterial Chemoembolization Market reflecting the standard practice of locoregional therapy during prolonged transplant waiting times that prevent tumor progression beyond Milan criteria and identify patients with favorable tumor biology suitable for transplant.

Milan criteria — single HCC nodule up to five centimeters or up to three nodules none exceeding three centimeters, without vascular invasion or extrahepatic spread — define the transplant eligibility threshold associated with acceptable post-transplant HCC recurrence rates that make transplantation the curative option for appropriate candidates. Patients meeting Milan criteria at listing face variable waiting times depending on regional organ availability, with waiting times of six months to over two years at high-volume centers creating the window during which tumor progression risks exceeding Milan criteria and disqualifying patients from transplant.

TACE as bridge therapy demonstrates tumor response rates of thirty to fifty percent for complete necrosis and stabilization in additional patients, with complete pathological necrosis at explantation analysis associated with favorable post-transplant outcomes confirming the prognostic value of TACE response. The Milan criteria compliance rate at transplant among listed patients receiving bridge TACE significantly exceeds the expected rate based on natural history without bridging, validating TACE's role in maintaining transplant eligibility.

Downstaging TACE — treating patients initially beyond Milan criteria to achieve tumor reduction within Milan criteria and restore transplant eligibility — is supported by evidence showing acceptable post-transplant outcomes in patients successfully downstaged, with UCSF downstaging protocol results demonstrating comparable post-transplant outcomes to initially within-criteria patients.

Do you think expanded transplant criteria beyond Milan supported by successful TACE downstaging evidence will become universally adopted, allowing more HCC patients to benefit from curative transplantation?

FAQ

What are Milan criteria for liver transplant in HCC? Milan criteria define HCC transplant eligibility as single tumor up to five centimeters or up to three tumors none exceeding three centimeters without vascular invasion, associated with post-transplant recurrence rates below fifteen percent justifying organ allocation.

Why is TACE used before liver transplantation? TACE bridge therapy prevents HCC progression beyond transplant eligibility criteria during waiting periods, maintains or improves tumor control while awaiting organ availability, and identifies favorable tumor biology through TACE response that predicts good post-transplant outcomes.

#TACEmarket #LiverTransplant #HCCbridge #MilanCriteria #TransplantOncology #BridgeTherapy